MedTrace Logo

Cardiometabolic Benefits of Omega-3 Polyunsaturated Fatty Acids

NCT03378232 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-02-20

No results posted yet for this study

Summary

Omega 3 fatty acids have been shown to provide a number of cardiometabolic benefits in both healthy and at risk populations. Specifically, the daily consumption of fish oil supplements has been reported to reduce blood triglyceride levels, and influence glucose homeostasis and whole-body inflammation. Furthermore, a number of cardiovascular effects (i.e. reduced blood pressure, reduced coagulation) have been found to result from omega-3 consumption, as well as influencing energy expenditure (i.e. resting metabolic rate). The goal of this study is to examine the cardiometabolic and cardiovascular effects that result from long-term consumption of omega-3 fatty acids.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo Olive Oil

Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.

DIETARY_SUPPLEMENT

High EPA Supplement

Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.

DIETARY_SUPPLEMENT

High DHA Supplement

Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.

Sponsors & Collaborators

  • Ontario Ministry of Agriculture, Food and Rural Affairs

    collaborator OTHER_GOV

  • University of Guelph

    lead OTHER

Principal Investigators

  • David M Mutch, PhD · University of Guelph

  • Phillip Millar, PhD · University of Guelph

  • Lawrence Spriet, PhD · University of Guelph

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-05
Primary Completion
2017-05-26
Completion
2017-05-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03378232 on ClinicalTrials.gov